Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer
/in Dendritic Cells, Hypernephroma, International Publications /von 2009-09-01 / Int. J. Oncol. 2009 Sep;35(3):569-81Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22Harnessing dendritic cells to generate cancer vaccines
/in Dendritic Cells, International Publications /von 2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:88-98Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers
/in Dendritic Cells, International Publications /von 2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:41-50Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2009-08-08 / Med. Oncol. 2010 Sep;27(3):736-42Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities
/in Dendritic Cells, International Publications, Soft Tissue Sarcoma /von 2009-08-01 / Expert Rev Anticancer Ther 2009 Aug;9(8):1065-71Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens
/in Dendritic Cells, Glioblastoma, International Publications /von 2009-08-01 / Stem Cells 2009 Aug;27(8):1734-40Killer dendritic cells and their potential for cancer immunotherapy
/in Dendritic Cells, International Publications /von 2009-07-18 / Cancer Immunol. Immunother. 2010 Jan;59(1):1-11Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice
/in Dendritic Cells, International Publications /von 2009-07-07 / Clin. Cancer Res. 2009 Jul;15(14):4612-21
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de